Emergent BioSolutions, Inc., enters $220 million vaccine partnership with BARDA

Emergent BioSolutions, Inc., recently announced plans to establish a center dedicated to the advanced development of medical countermeasures.

The Rockville-based biotech firm said it has entered into a public-private partnership with the Biomedical Advanced Research Development Authority to create the Center for Innovation in Advanced Development and Manufacturing, according to

In addition to the development of medical countermeasures, the center aims to ensure the existence of a pandemic influenza vaccine manufacturing capability and to provide workforce development training programs to address the preparedness needs of the U.S. government.

"Emergent is pleased to enter into this long-term public-private partnership with BARDA to help achieve our common goal of strengthening national security and preparedness efforts," Daniel J. Abdun-Nabi, the president and chief executive officer of Emergent BioSolutions, Inc., said, reports.

The center's contract is valued at approximately $220 million over a period of eight years. It has 17 additional one year options that will specify their own period of performance and contract value. The eight year base period of performance includes securing a pandemic influenza vaccine candidate, constructing additional facilities to ensure its production and obtaining facility licensure to manufacture it at a Baltimore facility.

"We are honored by the U.S. government's continued confidence in us, which is founded on our longstanding track record of being the premier biodefense developer and supplier of medical countermeasures," Abdun-Nabi said, according to "This award underscores Emergent's core competencies not only in product development and manufacturing, but also our expertise in contracting with the U.S. government and navigating the regulatory process. This partnership truly allows us the opportunity to fulfill our mission - to protect life."